A study presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition compared the outcome of patients with large B-cell lymphoma (LBCL) who received chimeric antigen receptor (CAR) T-cell therapy vs autologous hematopoietic cell transplantation (auto-HCT) while in a complete response (Abstract 781).
